<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DFDF0845-BB1F-41CD-81DB-9EE43C8DA1EC"><gtr:id>DFDF0845-BB1F-41CD-81DB-9EE43C8DA1EC</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Wilson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F57F7D82-D2BD-4641-85A8-69EBDE320FE6"><gtr:id>F57F7D82-D2BD-4641-85A8-69EBDE320FE6</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:surname>Burchell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501531"><gtr:id>D30AE66A-5EAF-40CC-A599-82B01F44F0B4</gtr:id><gtr:title>Hormonal modulation of lung Na transport</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501531</gtr:grantReference><gtr:abstractText>The cells which line the interior surface of the lung possess molecular pumps and channels which together provide a mechanism for driving fluid movement across the walls of the lung. Their normal functioning is crucial before, during and after birth. Thus, before birth, the secretion of fluid into the lung generates a liquid template around which the developing airspaces grow. At birth, this fluid must be absorbed if the newborn baby is to breathe normally. However, from birth through childhood into adult life, the interior of the lung, although air-filled, is lined by a thin film of liquid - the volume and composition of which is very precisely regulated by adrenaline (the rapid acting ?flight or fight? hormone), long acting hormones such as thyroid and steroid hormones. Disrupting these regulating mechanisms underlies a number of serious lung disorders, including respiratory distress of the newborn, pulmonary oedema (e.g. altitude sickness) and cystic fibrosis. The work described in this application will define the ways in which the molecular channels involved in fluid absorption are controlled in order to keep the lungs dry and thus allow lung function to be maintained.</gtr:abstractText><gtr:technicalSummary>Na absorption transport by the epithelia that line the distal airways / gas exchanging regions of the lung is crucial to development and maintenance of lung function. At birth, Na absorption thus drives the removal of liquid from the lung, which is essential if the new borne infant is to breath, and postnatally, the luminal surface of the lung is covered by a thin film of liquid whose volume and composition must be precisely regulated by the controlled absorption of Na. Disordered pulmonary Na transport thus contributes to lung diseases as diverse as respiratory distress in the newborn, pulmonary oedema, and cystic fibrosis. Hormones which evoke increased Na transport do so by mechanisms which include (i) control over the expression of genes encoding the subunits that together form the epithelial Na channel (ENaC) and (ii) increased expression of an important regulatory enzyme, serum and glucocorticoid regulated kinase (SGK) that can control the number of such channels resident in the apical membrane. However, despite its clear importance, the relative significance of these two regulatory mechanisms, and the way in which these two mechanisms are interrelated to each other, are not well understood. The proposed experiments will address these issues using methods that allow the transcription of the ENaC and SGK genes (luciferase-linked reporter genes) to be studied, together with measurements that will assess the efficiency of ENaC trafficking to the plasma membrane (assays of surface abundance of FLAG-tagged ENaC). These experiments will be undertaken using a cellular model system (H441 cells) that has been shown to retain the important physiological features of the distal lung epithelium. It is anticipated that the new information provided by these studies will fuel the development of novel therapeutic strategies for clinically important lung diseases, but our data may well have broader significance since regulated Na transport also plays important roles in the integrated function of the reproductive and gastrointestinal tracts and is central to the control of whole body Na content, and hence blood pressure.</gtr:technicalSummary><gtr:fund><gtr:end>2010-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>309852</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>162703</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:id>80844A37-1CEB-4E19-B082-67FE80D55C23</gtr:id><gtr:outcomeId>VxWq7W9K6BA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wyeth Pharmaceuticals</gtr:department><gtr:description>Collaboration with Scientists at Wyeth (Penn. USA)</gtr:description><gtr:end>2010-06-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>FC23A8B6-1BAB-4D69-BEB6-C20C705565D4</gtr:id><gtr:outcomeId>A9872EA11FB0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship</gtr:description><gtr:end>2008-09-02</gtr:end><gtr:fundingOrg>George John and Sheilah Livanos Charitable Trust</gtr:fundingOrg><gtr:id>0B50FBE5-3018-4798-9DEB-7C26982AAEBE</gtr:id><gtr:outcomeId>6E65963E2B10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DTA Studentship</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FA0CC0D3-C14E-4E8F-B847-5E47441EC0FD</gtr:id><gtr:outcomeId>62A209B43C60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>53BFACF8-15C0-430A-BCFD-6D40E9415D47</gtr:id><gtr:title>Effects of nominally selective inhibitors of the kinases PI3K, SGK1 and PKB on the insulin-dependent control of epithelial Na+ absorption.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b48cb8e19c8cd949e2eab560a05f187"><gtr:id>7b48cb8e19c8cd949e2eab560a05f187</gtr:id><gtr:otherNames>Mansley MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>AEciFMBKURc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D750F270-BCBC-498D-9840-75B20CB84771</gtr:id><gtr:title>Dysregulation of epithelial Na+ absorption induced by inhibition of the kinases TORC1 and TORC2.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b48cb8e19c8cd949e2eab560a05f187"><gtr:id>7b48cb8e19c8cd949e2eab560a05f187</gtr:id><gtr:otherNames>Mansley MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>PvPxs5kr6mg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E1A8881-47D5-4CD3-A1FC-F37318F801D9</gtr:id><gtr:title>Glucocorticoids can activate the alpha-ENaC gene promoter independently of SGK1.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1a98b07afda0d3b0de37898cdd67c3e"><gtr:id>d1a98b07afda0d3b0de37898cdd67c3e</gtr:id><gtr:otherNames>McTavish N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>791FE5FA432</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6F4A157-8C8F-4531-B6C0-4720F38D69F7</gtr:id><gtr:title>SGK1 activity in Na+ absorbing airway epithelial cells monitored by assaying NDRG1-Thr346/356/366 phosphorylation.</gtr:title><gtr:parentPublicationTitle>Pflugers Archiv : European journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88bfe0ba6856f1ae16db832c3814748f"><gtr:id>88bfe0ba6856f1ae16db832c3814748f</gtr:id><gtr:otherNames>Inglis SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0031-6768</gtr:issn><gtr:outcomeId>73769224B36</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501531</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>